For decades, the inflammation detected in diseased heart muscle was treated as collateral damage — a consequence of cardiomyopathy rather than a cause. A comprehensive new synthesis challenges that assumption with meaningful implications for how millions of people with inherited or acquired heart muscle disease might eventually be treated.
This review, published in Cells, maps the inflammatory architecture underlying five structurally and genetically distinct cardiomyopathies: hypertrophic cardiomyopathy, Anderson-Fabry disease, cardiac amyloidosis, arrhythmogenic cardiomyopathy, and dilated cardiomyopathy. Despite their different origins — ranging from sarcomeric gene mutations to lysosomal enzyme deficiency to protein misfolding — all five conditions appear to converge on a shared immune circuit. Endogenous triggers including misfolded amyloid fibrils, accumulated glycosphingolipids, mechanical wall stress, and viral genetic material function as damage-associated molecular patterns (DAMPs), activating Toll-like receptors, the NF-κB transcription pathway, and the NLRP3 inflammasome. The resulting pro-inflammatory microenvironment drives fibroblast reprogramming, myocardial edema, and progressive fibrotic or fibro-fatty remodeling — the structural changes most responsible for arrhythmia, heart failure, and sudden death.
What makes this analysis potentially consequential is the therapeutic implication of convergence. Historically, cardiomyopathy treatment has been disease-specific — enzyme replacement for Fabry disease, tafamidis for amyloidosis, ICD implantation for arrhythmic subtypes. If a unified inflammatory bottleneck operates across phenotypes, targeted immunomodulation — such as NLRP3 inhibitors or selective NF-κB pathway blockade — could represent a cross-cutting intervention strategy. Several such agents are already in early-phase cardiovascular trials. The key limitation here is that this is a narrative review, not primary data; causal direction between inflammation and structural progression remains incompletely established in most subtypes. Still, as a framework for risk stratification and trial design, this synthesis is more integrative than incremental — it reframes myocardial inflammation from footnote to central mechanism.